Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)

Viktor Grünwald,Philipp Ivanyi,Stefanie Zschäbitz,Manfred Wirth,Peter Staib,Martin Schostak, Philip Dargatz,Lothar Müller,Michael Metz,Lothar Bergmann,Thomas Steiner,Martin Welslau,Anja Lorch, Reza Rafiyan,Eva Hellmis,Cristopher Darr,Philipp Schütt,Johannes Meiler,Thomas Kretz,Wolfgang Loidl

European Urology（2023）

引用 0|浏览18

暂无评分

摘要

For patients with metastatic renal cell carcinoma who received tyrosine kinas inhibitor (TKI) induction therapy, a switch to nivolumab for maintenance therapy had lower efficacy than TKI continuation. Our study indicates that patients who respond to a TKI should continue treatment. Future studies should explore the role of biomarkers to guide therapy selection.

查看译文

关键词

Metastatic renal cell carcinoma,Nivolumab,Tyrosine kinase inhibitor,Switch maintenance therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要